April 26, 2012 -- 3D Biomatrix, which develops and sells tools that mimic the human cellular environment for drug discovery research and testing, has been awarded a Phase I STTR grant from the National Institutes of Health (NIH) for further development of its Perfecta3DTM Hanging Drop Plates to develop a three-dimensional (3D) cell assay for metastatic prostate cancer.
3D Biomatrix, a life sciences company developing and marketing revolutionary solutions for three dimensional (3D) cell cultures, was recently awarded a Phase I STTR grant from the National Institutes of Health (NIH) for the development of a high throughput drug screening metastatic prostate cancer assay utilizing 3D Biomatrix’s Perfecta3D Hanging Drop Plates. The effort for this grant will be shared by 3D Biomatrix and the laboratory of Professor Shuichi Takayama at the University of Michigan.
Despite the high prevalence of prostate cancer among men in the United States, there is a lack of effective therapies against metastatic versions of the disease. The work described in the STTR grant will facilitate the development of better drugs by providing a high throughput assay that mimics prostate cancer metastasized to bone.
“Three-dimensional cell cultures provide in vitro models that mimic tissues that cannot be modeled in two-dimensions, such as prostate cancer metastasized to bone. The work described in this grant will make this 3D model available in a format ideal for drug discovery.” said 3D Biomatrix CEO Laura Schrader. “The impact for potential treatments is huge.”
Perfecta3D Hanging Drop Plates have been used to mimic prostate, breast, colon, kidney, and other cancers. The Plates are currently available from 3D Biomatrix.
About the Company
3D Biomatrix, LLC is a life sciences company developing and marketing revolutionary solutions for three dimensional (3D) cell cultures. Cells grown on 3D Biomatrix products have been shown to retain a much higher complexity of body response than cells grown in traditional two-dimensional plates and flasks.